SEC Form 4 · accession 0001209191-18-050575
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederic Pla
Officer — Chief Bus & Prod Dev Officer
Period of report
Sep 10, 2018
Accepted (ET)
Sep 11, 2018 · 7:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 10, 2018 | M | 1,500 | $27.00 | A | 37,038 | D | |
| Common StockF2,F3,F4,F1 | Sep 10, 2018 | S | 1,100 | $62.6818 | D | 35,938 | D | |
| Common StockF2,F3,F5,F1 | Sep 10, 2018 | S | 400 | $63.7925 | D | 35,538 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) HoldingF6 | $27.00 | Sep 10, 2018 | M | 1,500 | D | — | Feb 16, 2026 | Common Stock | 1,500 | 58,700 | D |
Explanation of responses
- F1Includes an aggregate of 18,734 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 7, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $62.46 to $63.08.
- F5Represents weighted average sale price. Actual sale prices ranged from $63.47 to $63.92.
- F6The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.